US › Healthcare

Viking Therapeutics Inc (VKTX)

US · Healthcare · Biotechnology

$32.94+1.01%
Last close · 2026-08-04

Latest quarter · ended 2026-06-30

Revenue
$0
Net profit
$-128.0M
Profit YoY
-95.3%
EPS
$-1.10
EPS estimate
$-1.21

EPS came in at -1.10 against a street estimate of -1.21 — a beat of 9.1%.

Key statistics

Market cap
$3.70B
Forward P/E
0.0
P/B
9.07
Book value
$4.33
EPS (TTM)
$-4.48
52-week high
$43.15
52-week low
$22.96
50-day MA
$34.01
200-day MA
$33.80
Beta
0.66

Analyst view

Analysts rate Viking Therapeutics Inc a buy (17 buy, 2 hold, 0 sell out of 19) with an average price target of $93.00.

Shareholding

Insiders
2.79%
Institutions
64.38%

Largest institutional holders

FundStake
BlackRock Inc5.90%
FMR Inc5.16%
Vanguard Capital Management, LLC4.30%
Vanguard Portfolio Management, LLC3.83%
Two Sigma Investments LLC3.80%
State Street Corp3.77%
Morgan Stanley - Brokerage Accounts2.58%
Geode Capital Management, LLC1.78%

Recent filings & reports

DocumentDate
Quarterly report · Q2 20262026-07-29
Results announced · Q3 20262026-07-29
Shareholder vote results · Q2 20262026-05-26
Quarterly report · Q1 20262026-04-30
Results announced · Q2 20262026-04-29
Proxy statement · Q2 20262026-04-01
Annual report FY20252026-02-11
Results announced · Q1 20262026-02-11

Readable in the app.

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Viking Therapeutics Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.